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Clinical treatment of B-cell chronic lymphocytic leukemia
(B-CLL) is limited by the progressive drug resistance and
nonselectivity of most drugs towards malignant cells. Depsi-
peptides are present in certain bacteria and display potent
antitumor activity. We have studied the effect of the novel
cyclodepsipeptide AT514 (serratamolide) from Serratia marces-
cens on B-CLL cell viability. AT514 induced apoptosis of B-CLL
cells from the 21 patients studied, as confirmed by Annexin-V
binding and nuclei condensation, with an average IC50 of 13 lM.
AT514 was effective in those B-CLL cases resistant to
fludarabine, but had no effect on normal PBL. AT514 preferen-
tially activated the intrinsic apoptotic pathway, as evidenced by
loss of mitochondrial membrane potential, release of cyto-
chrome c and activation of caspase-9 and -3, but not of
caspase-8. Importantly, AT514 interfered with phosphatidylino-
sitol-3 kinase and protein kinase C survival signals since it
increased the apoptotic effect of LY294002 and BisI inhibitors,
and induced Akt dephosphorylation at Ser 473. AT514 also
decreased NF-jB activity by dramatically reducing the levels of
p65 in B-CLL. This was confirmed on functional assays using
NF-jB-luc-transfected Raji cells and transgenic mice. Our
results establish that AT514 induces apoptosis of primary
B-CLL cells and could be useful for clinical treatment of this
malignancy.
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Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by
the progressive accumulation of monoclonal CD5þ B lympho-
cytes arrested in the G0/G1 phase of the cell cycle.
1,2 Malignant
cell accumulation is mainly due to inhibition of apoptosis rather
than to increased proliferation.3 Indeed, protein kinases
involved in survival pathways, such as phosphatidylinositol-3
kinase (PI3-K), protein kinase C (PKC) and Akt/protein kinase B,
are constitutively activated in B-CLL.4–6 Likewise, the activity of
the NF-kB family of transcription factors is also constitutively
high in B-CLL.6,7 Consequently, the expression of many genes,
including those that regulate apoptosis such as the Bcl-2 family,
is altered in this malignancy3,8 and is modulated in vitro during
spontaneous and drug-induced apoptosis.9,10 Chemotherapeutic
drugs, such as fludarabine, chlorambucil, prednisone, and
certain monoclonal antibodies directed to specific cell surface
proteins, also induce B-CLL apoptosis in vivo, although
complete remission is difficult to attain and all patients
eventually relapse.11 It is therefore important to search for
new agents which may be useful as novel therapies for B-CLL,
alone or in combination with already known drugs.
Depsipeptides are naturally present in certain bacteria strains
and have been shown to display antitumor activity.12 The
depsipeptide FR901228, for example, is a histone deacetylase
inhibitor that induces cell death in many solid tumors, T cell
leukemias and multiple myeloma.13 FR901228 also induces
apoptosis of B-CLL cells and is currently under clinical trials for
treatment of this malignancy.14,15 Depsipeptides may therefore
be potent therapeutic agents for B-CLL.
During the search for new potential anticancer agents, we
isolated the compound AT514 from cultures of Serratia
marcescens and identified it as the water-insoluble cyclic
depsipeptide serratamolide.16 We have investigated the activity
of this compound and recently found that AT514 inhibits cell
growth and induces apoptosis of several cell lines derived from
breast, lung and colon human tumors, as well as from T-cell
leukemia or Burkitt lymphoma (Soto-Cerrato et al., submitted for
publication). In the present report, we have studied the effect of
AT514 on primary B-CLL cells. We show that AT514 induces
apoptosis of these cells by affecting the Akt survival pathway
and this involves reduction in NF-kB activity, modulation in
expression of Bcl-2 family members and caspase activation.
Materials and methods
Patients, B-CLL cell purification and normal peripheral
blood lymphocytes (PBL)
A total of 21 patients with B-CLL diagnosis according to
established clinical and laboratory criteria were studied; 19 of
them had not received treatment at the time of this study. CD5þ
B-lymphocytes were purified from the peripheral blood of these
patients after informed consent, by Ficoll–Hypaque (Nycomed,
Oslo, Norway) centrifugation. PBL from healthy donors were
purified from buffy coats by Ficoll–Hypaque centrifugation,
passage through anti-CD14-conjugated microbeads and MACS
separation columns (Miltenyi Biotec, Bergisch Gladbach,
Germany) to remove monocytes.
Analysis of mitochondrial membrane potential (Dcm)
and cytochrome c release
For Dcm measurements, B-CLL cells were incubated for 24 h
with or without 20mM AT514 and treated for 20 min with 20 nM
DiOC6 (Cabiochem) at room temperature in the dark. Cells were
washed, resuspended in PBS and analyzed by flow cytometry.
For analysis of cytochrome c release into the cytosol, 30 106
cells were incubated for 24 h with or without 20 mM AT514.
Cells were washed once in cold PBS and gently lysed in 200ml
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ice-cold lysis buffer (25 mM Tris pH 6.8, 80 mM KCl, 250 mM
sucrose, 1 mM EDTA, 1 mM DTT, 0.1% digitonin, 10 mg/ml
leupeptin, 1mg/ml aprotinin, 1 mg/ml pepstatin, 0.1 mM phenyl-
methylsulfonyl fluoride). After centrifugation at 12 000g, 41C,
5 min, the cytosolic fraction was recovered in the supernatant
and its protein content determined by the BCA assay (Pierce,
Rockford, IL, USA). Equal amounts of protein were analyzed on
15% polyacrylamide SDS-PAGE and by Western blotting.
Analysis of NF-kB activity in transgenic mice and
transfected Raji cells
Transgenic mice containing the NF-kB luciferase reporter gene
were obtained from Dr Mercedes Rinco´n (University of
Vermont, Burlington, USA).17 Lymphocytes isolated from the
spleen of these mice or Raji cells transfected with the NF-kB-luc
or D3005 plasmids were cultured for 24 h in the absence or
presence of 20 mM AT514. Incubation with anti-CD40 mAb was
for 6 h. 10 106 cells for each condition were lysed in 40ml
passive lysis buffer (Promega Co., Madison, WI, USA) for 20 min
at room temperature. After centrifugation, 20ml of each super-
natant was added to 50 ml luciferase substrate (Promega) and
luciferase activity was determined on a TD-20/20 luminometer
(Turner Designs, Sunnyvale, CA, USA) and normalized with
respect to the total amount of protein in each supernatant and
transfection efficiency, if applicable.
Results
AT514 induces apoptosis of B-CLL cells
To determine the effect of AT514 on B-CLL cell viability, cells
from the 21 patients studied were incubated with various
concentrations of AT514 for 24 h and their viability was
measured by the MTT assay. Table 1 (Supplementary Informa-
tion) lists the results obtained for each individual patient and
Figure 1a represents the mean viability for the 21 cases. As can
be observed, control cells, which received no drug, were highly
viable (86% average) after 24 h. However, AT514 clearly
induced B-CLL cell death in a dose-dependent manner, with
an IC50 of 13mM (Figure 1a). For comparison, we also treated the
21 cell samples with fludarabine, a drug known to induce
apoptosis of B-CLL cells in vitro and commonly used for clinical
treatment of these patients.11 While most samples were sensitive
to fludarabine after 48 h (not shown), patients 4, 10, 11, 12 and
18 were resistant to this drug (5–15% cell death, not shown), but
were clearly sensitive to AT514 (Supplementary Table 1).
Therefore, in these cases, AT514 appeared to be a more
efficient agent in inducing B-CLL cell death. We also measured
the effect of AT514 on normal PBL. As shown in Figure 1b,
AT514 had a very limited effect on these cells decreasing their
viability only to 75% after 24 h of treatment.
To confirm that the cell death induced by AT514 was due to
apoptosis, we first measured by flow cytometry the exposure of
membrane phosphatidylserine using FITC-labelled Annexin V,
and of cellular DNA using propidium iodide. As shown in
Figure 2a for patient 4, AT514 had very little effect after 6 h of
exposure as only 4.9% of cells were early apoptotic (Annenxin-
Vþ , PI). However, after 15 h of AT514 treatment, the
percentage of early and late (Annexin-Vþ , PIþ ) apoptotic
cells increased (Figure 2a). After 24 h of exposure to AT514,
66.7% of cells were late apoptotic (Figure 2a). At this time, 4.2%
of control cells were early apoptotic and 22.9% late apoptotic
(Figure 2a). We also studied whether AT514 induced nuclei
condensation and/or fragmentation. B-CLL cells were incubated
with or without 20 mM AT514 for 24 h and stained for actin with
TRITC-phalloidin (not shown) and with Hoechst to visualize the
nucleus. As shown in Figure 2b, control cells contained an intact
and uniformly stained nucleus, while cells treated with AT514
had condensed nuclei, characteristic of apoptotic cells. These
results therefore indicated that AT514 induced apoptosis of
B-CLL cells.
AT514 disrupts the mitochondrial membrane potential,
induces release of cytochrome c and activates caspase-9
and -3
To determine the role of mitochondria in AT514-induced
apoptosis, we first studied whether AT514 affected the
mitochondrial membrane potential. B-CLL cells from patients
4 and 13 were incubated for 24 h in the absence or presence of
20 mM AT514, treated with DiOC6 and analyzed by flow
cytometry. As shown in Figure 3a, AT514 induced a loss of
the mitochondrial membrane potential, increasing the number
of DiOC6-negative, apoptotic cells in both cases. We then
analyzed by Western blotting the release of cytochrome c to the
cytosolic fraction after treatment of B-CLL cells with AT514. As
shown in Figure 3b for patients 4 and 13, cytochrome c was
clearly increased in this fraction compared to the control. To
determine if this resulted in activation of the initiator caspase 9,
B-CLL cells were cultured for 24 h with or without 20 mM AT514,
lysed and analyzed by Western blotting. As shown in Figure 3c
for five different patients, AT514 effectively induced cleavage of
46 kDa procaspase-9 to the active form of 35 kDa. Likewise,
PARP, a substrate of the effector caspase-3, was processed in
these lysates and in lysates from cases 6, 9 and 16 (data not
shown), from the native 116 kDa form to the 85 kDa product,
indicating that caspase-3 had been activated by caspase-9.18
Indeed, immunoblotting analyses confirmed the processing of
caspase-3 from the native 32 kDa form to the 17 kDa active
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Figure 1 (a) Effect of AT514 on B-CLL cell viability. B-CLL cells
were incubated in 96-well plates (2 105 cells/100ml) with or without
the indicated concentrations of AT514. After 24 h, cell viability was
determined by the MTT method. All determinations were carried out
in triplicate and values represent the average of the 21 cases studied.
(b) PBL from four different healthy individuals were incubated as
above and the viability was measured after 24 h. Determinations were
carried out in triplicate and values are the average of the four cases
studied.
Depsipeptide AT514 induces apoptosis in B-CLL
E Escobar-Dı´az et al
573
Leukemia
subunit (shown in Figure 3c for patients 4, 13 and 20). To further
characterize the apoptotic pathway involved, we analyzed the
possible activation of caspase-8, another initiator caspase which
can also activate caspase-3. As shown in Figure 3d for patients
4, 13 and 20, no significant decrease in procaspase-8 levels was
observed. Consequently, cleavage of the caspase-8 substrate Bid
was not observed (Figure 3d). Altogether, these results suggested
that AT514 primarily activated the intrinsic apoptotic pathway
in B-CLL.
AT514 decreases the Bcl2/Bax ratio in B-CLL cells
To establish whether AT514 regulated the Bcl-2/Bax ratio, we
measured the levels of both proteins in lysates of B-CLL cells
from seven different patients, treated with or without 20 mM
AT514 for 24 h. We found that AT514 consistently increased the
levels of Bax (proapoptotic) and generally decreased the levels
of Bcl-2 (antiapoptotic) (Supplementary Figure 1). Consequently,
the Bcl-2/Bax ratio was greatly reduced in samples treated with
AT514 compared to controls for the seven patients studied
(Table 2, Supplementary Information).
AT514 affects the PI3-K/Akt survival pathway
Previous studies have shown that PI3-K and PKC are constitu-
tively activated in B-CLL cells and contribute to the survival of
these cells.4–6 To determine whether AT514 was affecting this
pathway, we first studied if AT514 enhanced the reported
apoptotic effect of LY294002 and BisI, inhibitors of PI3-K and
PKC, respectively.4,5 To this end, we used suboptimal concen-
trations of AT514 (10 mM) and of both inhibitors (20 and 5mM,
respectively). Cells were incubated with inhibitors for 1 h prior
to adding AT514. Figure 4a shows representative results for two
patients out of the four studied with identical results. When used
individually, AT514, LY294002 and BisI produced partial B-CLL
apoptosis. However, when AT514 was combined with either
inhibitor, apoptosis increased in all four cases, and the
combination of AT514 with both LY294002 and BisI further
reduced cell viability to 10–15% (shown in Figure 4a for patients
13 and 18), suggesting that AT514 was cooperating with both
kinase inhibitors. Incubation with the ERK inhibitor U0126
(5 mM) had no effect on B-CLL viability, in agreement with
previous reports4,5 and the combination of U0126 with AT514
did not modify this effect (Figure 4a).
We next examined if AT514 affected the phosphorylation of
Akt, the key effector of PI3-K-dependent survival signaling. As
shown in Figure 4b for patients 13 and 18, Akt was
phosphorylated in control cells after 24 h of culture. However,
treatment with AT514 clearly inhibited Akt phosphorylation in a
dose-dependent manner. As a control, incubation with
LY294002 also inhibited Akt phosphorylation in both cases
(Figure 4b), confirming that Akt activation was PI3-K dependent.
These results suggested that AT514 was inhibiting the PI3-K/Akt
survival pathway in B-CLL cells.
Propidium iodide
An
ne
xi
n 
V-
FI
TC
6 h 15 h 24 h
Control
+ AT514
Control AT514
2.8 13.8
0.2
83.2
2.8 16.9
80.2
0.1
4.2 22.9
72.7
0.2
4.9 11.3
83.7
0.1
13.5 34.2
52.2
0.1
8.1 66.7
25.1
0.1
a
b
Figure 2 AT514 induces apoptosis in B-CLL cells. (a) B-CLL cells from patient 4 were treated with or without 20mM AT514 for the indicated
times, washed and incubated with Annexin V-FITC and propidium iodide and analyzed by flow cytometry. Numbers represent the percentage of
cells in each compartment. (b) Cells from patient 4 were treated with 20mM AT514 for 24 h, placed in poly-D-lysine-coated coverslips and stained
with Hoechst. Bar, 10mm.
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AT514 decreases NF-kB activity
Akt suppression of apoptosis has been shown to involve the NF-
kB transcription factor.19,20 Consequently, NF-kB activity is
constitutively high in B-CLL cells.6,7 To determine if NF-kB was
affected by AT514, we first analyzed by Western blotting the
levels of NF-kB in the nuclear and cytosolic fractions of lysates
of B-CLL cells treated with AT514. Figure 5a shows that in
control cells NF-kB was present in both fractions, indicating a
certain basal activity (NF-kB in the nucleus), as reported.6,7
Treatment with AT514 dramatically reduced the levels of NF-kB
in both fractions (Figure 5a), suggesting that AT514 was blocking
the biosynthesis and/or transcription of NF-kB. To establish that
this resulted in a reduced NF-kB activity, we took advantage of
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Figure 3 AT514 primarily activates the mitochondrial apoptotic pathway in B-CLL. (a) Flow cytometric analysis of the loss of mitochondrial
membrane potential (Dcm) after incubation of B-CLL cells with 20mM AT514 for 24 h. (b) 30 106 B-CLL cells were treated or not with 20mM
AT514 and lysed. Protein (100mg) from the cytosolic fractions was analyzed by Western blotting using an anti-cytochrome c Ab. (c) AT514 induces
activation of caspase-9 and -3 and PARP cleavage. B-CLL cells from the indicated patients were incubated with or without (C, control) 20mM
AT514 for 24 h. Cells were then lysed and analyzed by Western blotting with specific antibodies. Conversion from the proactive forms of caspase-9
(46 kDa) and caspase-3 (32 kDa) to the active enzymes of 35 and 17 kDa, respectively, as well as the cleaved product (85 kDa) of PARP is
indicated. (d) Lysates were also analyzed for caspase-8 activation and Bid cleavage using specific antibodies. Quantitation of protein bands was
performed by the ECL method and values were corrected using actin as an internal control. Reduction in the levels of pro-caspase-8 (55 kDa) and
Bid (23 kDa) was not observed.
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the NF-kB-luc reporter plasmid.21 Owing to the difficulty of
transfecting primary B-CLL cells, we used the B lymphoma cell
line Raji for these experiments. AT514 effectively induced
apoptosis of Raji cells in a dose-dependent manner (Figure 5b).
These cells were transfected with NF-kB-luc or the control
D3005 plasmid, incubated with or without 20 mM AT514 for
24 h, lysed and their activity was analyzed on a luminometer.
Figure 5c shows that AT514 clearly reduced the luciferase
activity displayed by untreated cells. This activity was also
reduced to similar levels by LY294002, confirming that the
NF-kB activity was regulated by PI3-K. NF-kB activity was
effectively enhanced by an anti-CD40 mAb (Figure 5c), in
agreement with a previous report.7 Control cells transfected with
D3005 had very low luciferase activity and this was not affected
by treatment with AT514, LY29002 or anti-CD40 mAb
(Figure 5c).
To further confirm that AT514 was inhibiting NF-kB activity,
we purified lymphocytes from the spleen of transgenic mice
containing the NF-kB luciferase reporter gene.17 As shown in
Figure 5d, these lymphocytes were partially sensitive to AT514,
which decreased their viability to 55% after 24 h. Incubation of
spleen lymphocytes from three different mice with AT514
clearly reduced the luciferase activity exhibited by untreated
cells (Figure 5e). The control LY294002 produced a similar
effect. These three sets of results clearly indicate that NF-kB
plays an important role in the apoptotic mechanism induced by
AT514.
Discussion
In this report, we show that the novel cyclodepsipeptide AT514
(serratamolide), naturally occurring in S. marcescens, is an
efficient inducer of apoptosis in B-CLL cells. The present results
expand our previous studies on established cancer cell lines
(Soto-Cerrato et al., submitted) and represent the first evidence
that AT514 induces apoptosis in human primary cancer cells.
The viability of B-CLL cells from the 21 patients studied here
clearly diminished when exposed to AT514. Our results show
that this was due to induction of apoptosis since cell death was
accompanied by Annexin-V uptake, nuclei condensation,
mitochondrial damage and caspase activation. Interestingly,
AT514 had very little effect on normal PBL and was effective in
the B-CLL cases that showed resistance to fludarabine, a drug
commonly used in the treatment of these patients. This suggests
that AT514 may be a very useful therapeutic agent for patients
who are totally or partially resistant to fludarabine. Other
differences between the mode of action of the two drugs include
the p53 pathway. It is well established that fludarabine induces
p53 expression22 and we have shown that interfering with this
expression by crosslinking a4b1 integrin induces cell survival.23
In results not shown, we did not observe induction of p53 in the
present study, thus ruling out a role for this protein in the AT514
apoptotic pathway.
Both the intrinsic and extrinsic apoptotic pathways have been
shown to operate in B-CLL. Thus, while some cytotoxic drugs
(chlorambucil, fludarabine, rolipram) and g-radiation activate
caspase-8 and subsequent effector caspases,24,25 induction of
apoptosis by anti-CD22 inmunotoxins mainly involved the
caspase-9 pathway.26 Concomitant activation of both initiator
caspases was also observed when apoptosis was induced by
acadesine27 or the histone deacetylase inhibitor MS-275.28 Our
present results indicate that AT514 preferentially activates the
intrinsic, mitochondria-mediated, apoptotic pathway in B-CLL,
since cytochrome c release and activation of caspase-9, but not
of caspase-8, was clearly evident. This could be an important
mechanistic difference with respect to the previously described
effect of depsipeptide FR901228, which activates the extrinsic,
caspase-8 mediated, apoptotic pathway in B-CLL.15 Another
major difference between depsipeptides FR901228 and AT514
is that FR901228 is a histone deacetylase inhibitor and was
shown to acetylate histones H3 and H4 concomitant with
induction of apoptosis.15 In the present report, we did not
observe increased acetylation of H3 and H4 histones upon
B-CLL treatment with AT514 (results not shown), indicating that
both depsipeptides activate different mechanisms for induction
of apoptosis.
Several reports have recently shown that protein kinases such
as PI3-K/Akt and PKC as well as the transcription factor NF-kB
are constitutively activated in B-CLL and contribute to the
defective apoptosis of these cells.4–6,29 Our present results
clearly show that AT514 interfered with this survival pathway,
since it significantly increased the apoptotic effect of specific
inhibitors for PI3-K and PKC. Moreover, we show that B-CLL
cells had constitutively phosphorylated Akt, in agreement with a
previous study,6 and AT514 induced Akt dephosphorylation at
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Figure 4 AT514 interferes with the PI3K/Akt survival pathway.
(a) B-CLL cells from two representative patients were incubated for 1 h
in the presence or absence of 20mM LY294002, 5 mM BisI, or 5 mM
U0126, prior to the addition of 10mM AT514. After 24 h, cell viability
was analyzed by flow cytometry using Annexin V and propidium
iodide. Values represent the average of duplicate determinations.
(b) B-CLL cells (10–20106) were incubated with or without 10 and
20mM AT514 or 20 mM LY294002 for 24 h and lysed. Akt phosphor-
ylation was analyzed by Western blotting using specific antibodies
against total Akt or the phosphorylated form (Ser 473) of this kinase.
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Ser 473. Constitutively activated Akt in B-CLL was not observed
in another report5 and this discrepancy remains to be explained.
Akt controls cell survival by inducing phosphorylation and
inactivation of proteins involved in apoptosis,30 but also by
activating NF-kB and thus the expression of survival genes.20 In
agreement with this pathway, we show in the present study that
AT514 dramatically reduced the total levels of the p65 NF-kB
component, thus directly affecting the activity of this transcrip-
tion factor in B-CLL. We used two independent functional
approaches, consisting of NF-kB-luc-transfected Raji cells and
NF-kB-luc transgenic mice, to confirm that AT514 inhibited
NF-kB activity. Our results clearly demonstrate that AT514
treatment induced a reduction in the activity of NF-kB in both
cases.
The present findings provide a mechanism for AT514
induction of apoptosis in B-CLL cells, primarily involving the
mitochondria-mediated apoptotic pathway and interference
with Akt/NF-kB survival signals. To our knowledge, this is the
first evidence showing a direct inhibition of Akt and NF-kB
activation by a depsipeptide in B-CLL. A previous report31 has
shown that FR901228 (another depsipeptide known to induce
apoptosis in B-CLL) diminished Akt activity of ras-transformed
10T1/2 cells, by reducing the total levels of this kinase. As we
show in our study, AT514 inhibited Akt phosphorylation in
B-CLL without affecting total Akt levels.
NF-kB controls the expression of several genes involved in
apoptosis, including members of the Bcl-2 protein family.32
Accordingly, we have found a highly consistent downregulation
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Figure 5 AT514 inhibits NF-kB activity. (a) B-CLL cells (10–20 106) from two representative patients were incubated for 24 h with or without
AT514; nuclear and cytosolic extracts were prepared and equal amounts of total protein were analyzed by Western blotting using an anti-p65
antibody. Actin was used as a loading control. (b) Raji cells were incubated with the indicated concentrations of AT514 and their viability
determined after 24 h by the MTT method. (c) NF-kB-luc- or C/EBP-luc-transfected Raji cells were incubated with AT514 for 24 h, lysed and the
luciferase activity determined on a luminometer. The effect of LY294002 and an anti-CD40 mAb is also indicated. The results from two
independent experiments are shown. Values were corrected for transfection efficiency and total protein content on each lysate. (d) Spleen
lymphocytes from NF-kB transgenic mice were incubated with the indicated concentrations of AT514 and their viability determined after 24 h by
the MTT method. (e) Luciferase activity of these lymphocytes after treatment with AT514 for 24 h. Three different mice were studied (exps 1, 2 and
3) and values are normalized according to the total protein content on each lysate.
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of the antiapoptotic protein Bcl-2 concomitant with induction of
apoptosis by AT514. In contrast, the levels of the proapoptotic
protein Bax were dramatically increased by AT514 treatment.
Although Bax is not under NF-kB control, it plays an important
role in B-CLL apoptosis by determining the Bcl-2/Bax ratio, an
important survival marker on these cells,2,3 and we show in this
report that AT514 consistently decreased this ratio. Bax may also
be playing a crucial role in the mitochondrial-mediated
apoptotic pathway initiated by AT514. It was recently shown
that induction of B-CLL apoptosis by proteasome inhibitors
produces a conformational change and mitochondrial translo-
cation of Bax, which does not require caspase activation.33
Although the initial stimulus that leads to these events is not
known yet, it is interesting that PI3-K and Akt activities prevent
Bax conformational change and translocation to mitochon-
dria.34,35 It is tempting to speculate that inhibition of PI3-K/Akt
by AT514 initiates Bax-mediated mitochondria perturbation and
subsequent caspase-9 and caspase-3 activation and apoptosis.
In conclusion, we show in this study that cyclodepsipeptide
AT514 is a novel apoptotic agent for primary B-CLL cells, which
directly blocks the PI3-K/Akt/NF-kB survival pathway and
activates the mitochondria-mediated apoptotic cascade. It is
noteworthy that several current cancer therapies are aimed at
the inhibition of this survival pathway.36 AT514 may therefore
constitute an efficient drug for the clinical treatment of B-CLL,
alone or in combination with conventional protocols.
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